Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Breaking Down Thursday’s Top 3 Unusually Active Options

In Thursday’s unusual options activity, there were 1,399, split almost evenly between puts (705) and calls (694). Of the top 100 by Vol/OI ratios, the top three ratios range from 81.86 to 69.31.

Barchart · Jun 6, 2025

Weight loss drugs linked to higher risk of eye damage in diabetic patients

Study finds medicines such as Ozempic associated with greater risk of developing age-related macular degeneration

The Guardian - UK · Jun 5, 2025

Tudor Pro, Uno-X and TotalEnergies scheduled to debut in Maryland Cycling Classic in September

Early commitments for women's race include Canyon-SRAM zondacrypto and EF Education-Oatly

Cycling News · Jun 5, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Barchart · Jun 1, 2025

The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies

From Novo Nordisk to UnitedHealth, onetime chief executives are returning to guide their former organizations in times of trouble.

Fortune · May 30, 2025

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

MarketBeat · May 23, 2025

Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’

Edward Fanelli, 57, shared his regrets about taking Ozempic after he was diagnosed with a rare eye condition.

The Independent UK · May 20, 2025

Read news from The Economist, FT, and more,
with one subscription

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Barchart · May 17, 2025

Stock Market Today: Investors Look on the Bright Side

A generally good week closes on another positive note, as investors, traders and speculators look for fresh catalysts.

Kiplinger · May 16, 2025

Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?

Novo Nordisk stock sinks as CEO Lars Fruergaard announces his resignation. Analysts are not happy with his departure but continue to see significant upside in NVO shares.

Barchart · May 16, 2025

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

International Business Times · May 16, 2025

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

Euronews · May 16, 2025

Is It Time to Buy the Dip in Novo Nordisk Stock?

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

MarketBeat · May 15, 2025

Europe's Biggest 'Green' Methanol Plant Opens In Denmark

Europe's largest "green" methanol plant opened in Denmark on Tuesday, boosting the continent's emissions reduction efforts -- with customers ranging from shipping giant Maersk to toymaker Lego and pharmaceutical firm Novo Nordisk.

International Business Times · May 13, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · May 13, 2025

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

The Independent UK · May 12, 2025

Health experts reveal weight-loss jabs can ‘prevent mealtime battles’ for children

Health experts presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and lifestyle plan they were already following

Evening Standard · May 12, 2025

Weight-loss jabs for children ‘are effective and help prevent mealtime battles’

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.

Fortune · May 9, 2025

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · May 7, 2025

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

Euronews · May 7, 2025

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

MarketBeat · May 6, 2025

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

MarketBeat · May 2, 2025

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.

Fortune · May 1, 2025

CVS customers can get weight-loss drug Wegovy at a discount for cash

But you'll have to pay cash.

Euronews · May 1, 2025

Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results.

The Independent UK · Apr 30, 2025

Ozempic is growing in popularity — it’s also sending people to the ER

An analysis of emergency visits related to the active ingredient in drugs like Ozempic and Wegovy has exposed a surprising effect

1 … 15 16 17 18

Coverage From

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.